Núñez Marina, Pérez-Olmeda Mayte, Díaz Beatriz, Ríos Pilar, González-Lahoz Juan, Soriano Vincent
Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain.
AIDS. 2002 Nov 22;16(17):2352-4. doi: 10.1097/00002030-200211220-00023.
Treatment of hepatitis B virus (HBV) with lamivudine may not completely suppress viral replication and often fails as a result of lamivudine resistance. Tenofovir is a new HIV inhibitor with further activity against HBV, which was explored in 12 HBV/HIV-co-infected patients with detectable levels of serum HBV-DNA, despite receiving a lamivudine-containing antiretroviral regimen. Lamivudine-resistance mutations were found in HBV from seven patients. HBV-DNA levels dropped a median of 3.78 logs from baseline to 24 weeks. Tenofovir was very effective at reducing HBV-DNA levels in HIV/HBV-co-infected patients carrying either wild-type or lamivudine-resistant viruses.
用拉米夫定治疗乙型肝炎病毒（HBV）可能无法完全抑制病毒复制，并且由于拉米夫定耐药性，治疗常常失败。替诺福韦是一种新型HIV抑制剂，对HBV也有活性，本研究对12例HBV/HIV合并感染患者进行了探索，这些患者尽管接受了含拉米夫定的抗逆转录病毒治疗方案，但血清HBV-DNA水平仍可检测到。在7例患者的HBV中发现了拉米夫定耐药突变。从基线到24周，HBV-DNA水平中位数下降了3.78个对数。替诺福韦在降低携带野生型或拉米夫定耐药病毒的HIV/HBV合并感染患者的HBV-DNA水平方面非常有效。
